July 20 (Reuters) - Amgen Inc
* FDA accepts biologics license application for Aimovig™ (erenumab)
* Amgen Inc - FDA has set a prescription drug user fee act (PDUFA) target action date of May 17, 2018.
* Amgen Inc - Aimovig will be jointly commercialized in U.S. by Amgen and Novartis. Source text for Eikon: Further company coverage: